Specialty Enzymes & Probiotics Obtains Product Licenses

Specialty Enzymes & Probiotics Receives Product Licenses Specialty Enzymes & Probiotics Receives Product Licenses from Health Canada for Three Spore-Forming Probiotics with Health Claims Specialty Enzymes & Probiotics announced that it has received product licenses from Health Canada for three spore-forming probiotics with health claims. The company has obtained product licenses for SEBiotic™ (Bacillus coagulans LBSC), SEBtilis™ (Bacillus subtilis PLSSC) and SEBclausii™ (Bacillus clausii 088AE). The three Bacillus probiotic strains were developed and studied to provide consumers with a range of health benefits. Each product has specific claims approved by Health Canada; further information regarding these claims is available from the company. Specialty Enzymes & Probiotics Chief Executive Officer and Founder Vic Rathi said, "We are excited that Health Canada has approved the natural health product license for these three probiotics. We work tirelessly to develop effective and marketable products for our customers. This is a great milestone, and we are excited to bring these ingredients to the Canadian market." Spore-forming probiotics are known for their ability to survive in harsh environments and remain stable throughout the digestive process. This allows them to reach the intestines and colonize the gut. There they can provide numerous health benefits, including helping reduce inflammation, promoting nutrient absorption, and supporting a healthy immune system. Specialty Enzymes & Probiotics is committed to providing high-quality, science-backed probiotic, enzyme and protein products to help support digestive health and overall wellness. With the approval of these three spore-forming probiotics, the company is positioned to make a significant impact on the health and wellbeing of Canadians. Source